Cui Bono? Finding Super Responders In Clinical Trials

I’m a voracious reader of mysteries in my spare time.  And some juncture in every story, as the detective finds himself staring at the corpse, they ask the inevitable question “Cui Bono — who benefits?”  Oddly enough, this is a question that doesn’t get asked often or early enough in the drug discovery and development process.

But that’s starting to change in translational medicine.  Recently, Memorial Sloan-Kettering launched an effort to identify so-called “super responders”.  These are patients whose disease went into remission after being given a drug or drug combination.  With the advent of low-cost whole genome- and tumor-sequencing, it’s now feasible to take a deeper look at the genomic characteristics of these super-responders in the hopes of being able to identify what makes them super-responders.  Ultimately, this information would be used to determine which patients are most likely to benefit from new treatments.


About Mark Fortner

I write software for scientists doing drug discovery and cancer research. I'm interested in Design Thinking, Agile Software Development, Web Components, Java, Javascript, Groovy, Grails, MongoDB, Firebase, microservices, the Semantic Web Drug Discovery and Cancer Biology.
This entry was posted in Cancer Research, Drug Development, Informatics, pancreatic cancer and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s